Richard Klausner
CIK 1591178 · Executive Chairman · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
JUNO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92122
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LYEL | Director | 190,557 | $9.82 | $1.87M | -$108.4K | 10 | 2026-06-12 |
| PBLS | Director | — | $26.33 | — | $0 | 1 | 2026-06-11 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 0 | — | — | -$10.49M | 27 | 2018-03-07 |
| ILMN | Sr VP, Chief Medical Officer | 22,847 | $277.93 | $6.35M | -$420.0K | 10 | 2016-02-01 |
Recent Filings · Page 4 of 6
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-10-17 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +401 | $0 | EDGAR |
| 2016-07-05 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +300 | $0 | EDGAR |
| 2016-06-24 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −12,000 | -$488.5K | EDGAR |
| 2016-06-21 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-20 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −12,000 | -$480.0K | EDGAR |
| 2016-04-19 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −12,000 | -$514.9K | EDGAR |
| 2016-04-07 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +300 | $0 | EDGAR |
| 2016-03-22 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −12,000 | -$480.0K | EDGAR |
| 2016-03-02 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −24,000 | -$970.0K | EDGAR |
| 2016-02-01 | ILMN | Tax (F) | −253 | -$40.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.